Cue the M&A chatter: UniQure is scouting for a buyout deal as gene therapy field sizzles — report
All the enthusiasm that’s been whipped up in the gene therapy field this past year has helped stoke the rumor mill about all sorts of possibilities for uniQure $QURE, which has seen a quick run-up on its share price. And now the biotech’s backers are getting a big boost from Bloomberg to keep the run going.
There’s no deal to report, but sources are telling the business news service that uniQure has brought in advisers to see what might be done — including a sale — with the pharma giants now prowling the clinical players for partners and acquisitions.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.